Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-438 Dose-Response in PPI-Resistant Erosive Esophagitis
NCT01630746Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2012
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vonoprazan in erosive esophagitis (EE), sponsored by Takeda. Started Jul 2012; status: completed.
02
Drugs
vonoprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT01630746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01630746.